TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presented Sat 29 Aug · 12:00 CESTHot Line 3All Hot Line trials →

EPIDAURUS

2026

Escalated Single Platelet Inhibition for One Month Plus Direct Oral Anticoagulation in Patients With Atrial Fibrillation and acUte coRonary Syndrome Undergoing percutaneoUS Coronary Intervention (EPIDAURUS)

In 602 patients with atrial fibrillation and ACS after PCI, one month of a potent P2Y12 inhibitor plus a NOAC did not reduce major ischaemic events at 6 weeks compared with clopidogrel plus a NOAC.

Result

Efficacy: Co-primary at 6 weeks: (1) major ischaemic events, the composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, ischaemic stroke, systemic thromboembolism or urgent revascularisation (superiority); (2) death or BARC type 2 or higher bleeding (non-inferiority)HR 3.54 (95% CI 1.15-10.85) · P = 0.028

Below 1 favours one month of a potent P2Y12 inhibitor plus a NOAC, above 1 favours clopidogrel plus a NOAC.

Also reported: Stopped early after 602 of a planned 1,474 patients. No difference in cardiovascular death, myocardial infarction or stroke at 6 weeks or 6 months.

Original publication
Subtopic
AF–PCI antithrombotics
Design
Investigator-initiated, multicentre, randomised, open-label trial with blinded outcome assessment (sponsor LMU Munich); 1:1 randomisation within 24 hours of successful PCI; co-primary endpoints at 6 weeks tested for superiority (ischaemic composite) and non-inferiority (death or bleeding)
Relevance
Supporting: context rather than must-know.
Source
Rizas KD, et al. Presented at ESC Congress 2026, Hot Line 3, 29 August; simultaneously published in Nat Med.doi 10.1038/s41591-026-04629-7

Discussion & critique

A question asked and answered in the direction nobody wanted: adding prasugrel or ticagrelor rather than clopidogrel to a NOAC after infarction tripled major bleeding and bought nothing ischaemic. The trial stopped at 602 of 1,474 patients, so the ischaemic comparison is underpowered and the bleeding interval is wide: 1.15 to 10.85, but the direction is unambiguous and the harm is the one that shows up first. Read as a boundary on the potent P2Y12 inhibitors in anticoagulated patients, not as a precise estimate.